Pfizer To Acquire Urology Agent Fesoterodine From Schwarz
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal also ends a patent dispute regarding fesoterodine and Pfizer's incontinence agent Detrol.
You may also be interested in...
Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor
Anti-muscarinic agent acquired from Schwarz in 2006 to hit U.S. market in 2009; in time to build sales before Pfizer’s Detrol goes off-patent in 2012.
Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor
Anti-muscarinic agent acquired from Schwarz in 2006 to hit U.S. market in 2009; in time to build sales before Pfizer’s Detrol goes off-patent in 2012.
Pfizer Blames Fesoterodine Partner Schwarz For Launch Delay
The company anticipates the incontinence therapy will launch in early 2009, nearly two years later than expected.